News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

Al's Comment:

 This article looks at the failure of the Nivolumab trial and tries to show why it failed and how we can overcome those failures. This trial used Nivolumab as a monotherapy at the time of first recurrence and it failed to show an improvement in overall survival. The authors say that it may work better in combination with some other treatments that boost the immune system, such as radiation, vaccines or other immunotherpaies.  It also may work better with newly diagnosed instead of recurrent patients.

 


Posted on: 12/07/2017

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc